Abstract: Erectile dysfunction (ED) is a prevalent condition that affects men and their partners. Signifi cant improvements in the sexual lives of these couples have been achieved with the introduction of phosphodiesterase 5 (PDE5) inhibitors. A PDE5 inhibitor is now widely recognized as the fi rst-line therapy for the majority of men with ED. Currently, three PDE5 inhibitors -sildenafi l, tadalafi l and vardenafi l -are approved to be taken as needed in anticipation of sexual activity, but only one of these, tadalafi l, has been approved to be taken once daily. The primary aims of this review are to summarize the patients' and partners' viewpoints of ED management with PDE5 inhibitors, and to determine whether once-daily tadalafi l can contribute to improving some psychological aspects of ED (such as sexual self-confi dence, spontaneity and time concerns) compared with on-demand tadalafi l or other PDE5 inhibitors taken by patients with ED.
Introduction
Male erectile dysfunction (ED) is a prevalent condition defi ned as the persistent inability to obtain and maintain an erection suffi cient to permit satisfactory sexual performance.
1,2 ED is now recognized as a comorbid condition, especially in men with cardiovascular disease and diabetes mellitus. 3 Moreover, ED also affects psychological health, eroding self-image, causing emotional distress, impairing marital relations and, therefore, compromising the quality of life of patients and their partners. 4, 5 Before the introduction of oral drugs, pharmacological ED treatment was limited to penile injections or intraurethral insertion of vasoactive agents or prostaglandin E1.
Use of a medication that inhibits phosphodiesterase type 5 (PDE5) is now widely recognized as the fi rst-line therapy for the majority of men with ED. 6, 7 Currently, three PDE5 inhibitors -sildenafi l, tadalafi l and vardenafi l -are approved to be taken as needed before anticipated sexual activity. Many factors can infl uence patient preference for an ED therapy: drug attributes (effi cacy, safety, tolerability and pharmacokinetic properties) as well as behavioral, psychological and relationship factors. Although PDE5 inhibitors are easy to use, men must ingest these oral agents on-demand before sexual activity, and thus remain temporally linked to treatment. For some patients and their partners, planning sexual activity around taking a drug is burdensome. Recent study results demonstrated that chronic administration, with tadalafi l 8 dosed at 2.5, 5 or 10 mg taken once daily, might offer another valuable option for ED treatment. 9, 10 In 2007, 2.5 and 5 mg tadalafi l for once-daily use were approved by the European Commission for the treatment of ED, and became available in many states of the European Union. Based on patient choice and physician assessment, tadalafi l for once-a-day use is for patients who already respond to PDE5-inhibitor therapy and who anticipate sexual activity at least twice weekly. Once-daily tadalafi l represents a new therapeutic approach, able to provide some men with uninterrupted treatment for their ED. Therefore, it eliminates the need for planning sex within a limited timeframe and restores or develops freedom and choice of the moment for intercourse as a function of the couple's expectations and/or desires. Using data from the scientifi c literature and clinical trials, we analyzed patients' and partners' viewpoints of ED management with PDE5 inhibitors, especially once-daily tadalafi l. This summary of our fi ndings suggests the interest expressed in an additional therapeutic approach for this indication.
PDE5-inhibitor therapy and ED
As recommended in the guidelines written by the majority of scientifi c associations, the fi rst-line therapy for most men with ED is an oral PDE5 inhibitor. These medications are now widely considered safe and effective ED treatments, with reported effi cacy rates of 60% to 70%. 2, 6, 11 Tadalafi l, one of the three PDE5 inhibitors currently on the market, is approved in more than 100 countries, including Australia, Brazil, Mexico, Canada, the United States and countries throughout Europe, as an oral treatment for ED. More than 18 million patients worldwide have been treated with tadalafi l since its fi rst introduction in February 2003. Like the other PDE5 inhibitors, it was fi rst developed and approved for the treatment of ED on an as-needed basis, with a recommended starting dose of 10 mg in most patients that may be increased to 20 mg or decreased to 5 mg, based on individual effi cacy and tolerability. PDE5 inhibitors are available by prescription only and are not for everyone. Men should discuss their medical conditions and all medications with their doctors to ensure that such a treatment is right for them and that they are healthy enough for sexual activity.
Until 2007, PDE5 inhibitors were taken on-demand by the majority of patients, being ingested prior to anticipated sexual activity. For the patient, in a way, taking an on-demand therapy assumes that he has a kind of appointment.
Indeed, on-demand PDE5-inhibitor use means making an appointment with oneself or one's partner at a given time during the day or week. Optimization of its on-demand use means that the man identifi es the time best adapted to satisfy his desire for sexual intercourse. Of course, he must be assured that his partner is of the same mind. So, the moment of sexual activity is determined by the couple and not the swallowing of the pill. Therefore, good usage of on-demand therapy requires the perfect harmony of the couple, associated with good lines of (non-verbal) communication, and pill intake before the onset of foreplay.
But some patients cannot foresee their desire for sexual intercourse in time for the tablet to be absorbed and become active. They want to have sex at the same time the desire strikes them. 12 Thus, he should have taken the pill in advance, sometimes with no certainty of having intercourse. Because of its long half-life and 36 to 48 hours of clinical effi cacy, tadalafi l was preferred by these patients. Some couples, for example, became accustomed to taking tadalafi l Friday evening to prepare for the possibility of having intercourse during the weekend. Other patients, and especially their partners, found their sexual desires to be inhibited by the idea of taking a pill. Their solution was to separate, as much as possible, the swallowing of the pill from the onset of sexual activity, so as to 'forget' ingesting the pill. Here again, because of on-demand tadalafi l's particularly well-adapted pharmacokinetic properties, especially its 17.5-hour half-life assuring activity for about 2 days, patients often chose it.
It is certainly this advantage of prolonged activity that explains why preference studies conducted over the past several years found that signifi cantly higher numbers of patients, and their partners, preferred starting or pursuing tadalafi l rather than sildenafi l or vardenafi l. [13] [14] [15] [16] [17] In a double-blind, crossover study, 215 men with ED were randomized to receive 4 weeks of treatment with tadalafi l 20 mg or sildenafi l 50 mg, followed by the alternative treatment after a 1-to 2-week drug washout, to take as needed up to once daily before sexual activity. In order to provide proper dosing instructions for each drug while maintaining investigators and/or patients blinding, two 'nonexistent' placebo arms were added in the protocol, stating that the patients could also be randomized to receive placebo with the tadalafi l or sildenafi l instruction set. However, it was not a true double-blind study as specifi c dosing instructions and statements concerning the onset and duration of action of the two PDE5 inhibitors may have introduced a source of bias. In this patient population, with a mean age of 49.8 years, chosen to mimic a new patient consulting his physician for treatment of ED, tadalafi l 20 mg was preferred to sildenafi l 50 mg (66.3% vs 33.7%, respectively; p Ͻ 0.001) for the initiation of ED therapy. The results of that study also showed that preference did not differ according to patients' age, duration of ED, order in which treatments were received or previous sildenafi l exposure. 13 Another study aimed to determine what percentage of ED patients currently taking sildenafi l would switch to tadalafi l. Among the 147 patients who were taking sildenafi l at stable fi xed doses of 25, 50 or 100 mg as needed and then received tadalafi l 20 mg, 133 (90.5%) preferred continuing Once-daily tadalafi l for erectile dysfunction oral therapy with tadalafi l and 14 (9.5%) with sildenafi l (p Ͻ 0.001).
14 To compare preference of sildenafi l or tadalafi l to treat ED in men naive to PDE5 inhibitors, 367 men with ED were randomized to receive sildenafi l for 12 weeks followed by tadalafi l for 12 weeks or vice versa. After treatment, 29% of men chose sildenafi l and 71% chose tadalafi l (p Ͻ 0.001) for ED therapy during an 8-week extension. 15 To compare sildenafi l, vardenafi l and tadalafi l, the three PDE5 inhibitors currently available, a prospective, fi xed-dose preference study was conducted, with a crossover design. All 90 patients who completed this study were naive to all ED treatments, including PDE5 inhibitors. Drug preference was assessed by evaluating subjective elements that the patients had taken into account in making their choices: 25 (27.8%) opted to continue sildenafi l, 18 (20%) chose vardenafi l and 47 (52.2%) preferred tadalafi l. Moreover, although the three medications markedly improved erectile function, statistically signifi cant differences in the International Index of Erectile Function (IIEF) score and responses to the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire were found between tadalafi l and the two other drugs (p Ͻ 0.0001), but not between sildenafi l and vardenafi l. 16 All these studies examined several variables, like effi cacy, impact on quality of life and self-esteem from a male perspective. But women should also be involved in assessment and treatment decisions when ED is a problem for their partners, and recommendations have been made that research should focus on the impact of ED on women and the couple, rather than simply the man. 18 In a recent prospective investigation, women were asked for the fi rst time which drug they preferred their partners to use when treated for ED, and why they preferred it. 17 According to those fi ndings, a large majority of women chose tadalafi l over sildenafi l (79.2% and 15.6%, respectively; p Ͻ 0.0001). The main reasons the women gave as infl uencing their treatment preference were more relaxed and natural experiences leading to more intimacy, enjoyment and increased sexual satisfaction, a longer lasting effect of tadalafi l, increased sexual frequency and the fl exibility offered by the drug in terms of time frames. As noted in that report, the female perspective, compared to that of men, refl ected the importance of factors above and beyond obtaining and maintaining an erection for sexual pleasure and enhancement of the couple's relationship.
For the patients, the factors most signifi cantly associated with treatment preference were differences in time concerns, choice of dose, intercourse satisfaction, number of sexual attempts, satisfaction with erection hardness and the absence of or only minor side effects. 19 Although preference studies have shown that all the PDE5 inhibitors were highly effective, the majority of patients seemed to prefer tadalafi l because it is easier to take, can be ingested at any time of the day, and its property of enabling them to achieve an erection, with sexual stimulation, long after taking the drug (eg, 8, 16 or 24 hours later), leading to higher sexual self-confi dence and spontaneity and fewer time concerns related to sexual encounters. 7, 19 However, poor treatment satisfaction was reported by some men using on-demand PDE5 inhibitors. They want to be independent of scheduling their love life and to disconnect treatment from sexual intercourse, to enable them and their partners to be free to love and to retrieve a sexual life like before. For these men, the constant association of swallowing a pill and sexual relations, inherent in using on-demand PDE5 inhibitors, could even be a source of psychological and behavioral distress.
As we indicated above, inquiries in large populations of men suffering from ED and treated with PDE5 inhibitors showed that some patients did not respond to on-demand therapies either because they found swallowing the pill just prior to having sex disturbing or they had diffi culty identifying when they would have such relations. 12 Use of on-demand tadalafi l, although preferred by them, did not correspond completely to their expectations, because they still had to take a pill in connection with sexual activity. They wanted not to be systematically and continuously obliged to link pill taking with sexual activity.
These observations motivated the development of a new therapeutic approach for this indication, with more frequent or chronic dosing of a PDE5 inhibitor. Therefore, some sexologists, andrologists and urologists devised a new dosing regimen, with tadalafi l taken 3 times per week, to determine whether this chronic PDE5-inhibitor dosing regimen might offer a valuable ED-treatment option.
Chronic-dosing regimen: the fi rst step
The Scheduled Use versus on-demand Regimen Evaluation (SURE) study was the fi rst comparative trial with an alternative dosing schedule. 20, 21 In 4262 men with ED, it investigated treatment effi cacy and patient preference for 20 mg tadalafi l taken on-demand (maximum one dose per day and before sexual activity) versus 3 times per week for 5 to 6 weeks. After a 1-week washout period, patients were crossed over to the alternate regimen for 5 to 6 weeks. At the end of ondemand and 3 times per week treatment period, a normal EF domain score (Ն26) was reported by 60.2% and 62.3% of patients. Both treatments were equally effi cacious and well-tolerated, but a substantial number of men preferred chronic dosing (42.2%) versus 57.8% for on-demand. Moreover, patients on the alternative dosing regimen (3 times per week) signifi cantly changed their sexual behavior and had sexual attempts distributed over a wide period of time post dosing, with 47% for on-demand and 71% for 3 times per week performed beyond the fi rst 4 hours post dosing, preferably in the evening and morning hours. 22 As the aim of this study was not to demonstrate the superiority of the 3 times per week regimen compared to the on-demand regimen, the results showed that the two regimens provide another treatment option by giving men with ED and their partners unique dosing fl exibility with tadalafi l. In a retrospective analysis of pooled data from clinical trials of tadalafi l using placebocontrolled and open-label study designs, the frequency of serious cardiovascular treatment-emergent adverse events (CVTEAEs) was shown to be low in all groups evaluated. 23 In addition, the CVTEAE rate in tadalafi l-treated patients was independent of the dosing regimen, on-demand or 3 times per week, and comparable with that for placebo-treated patients, thereby demonstrating the safety of the chronicdosing regimen.
Despite the potential advantages of chronic dosing compared to on-demand regimens, taking a treatment 3 times per week seems not to be very easy and convenient for a majority of men with ED. They must note and remember on what days of the week the medication has to be taken. In response to these considerations, a new daily-dosing regimen was investigated, which also allowed a lower PDE5-inhibitor dose to be taken.
IPDE5 and daily dosing: a new treatment option
Tadalafi l differs in several ways from the other two PDE5 inhibitors currently available. Its molecule belongs to a distinct chemical class characterized by a different structure. Because of its T max of 2 hours, tadalafi l starts to take effect 16 to 60 minutes after intake. Its plasma half-life (T½) is 17.5 hours, as opposed to 4 to 5 hours for sildenafi l and vardenafi l, which results in improved erectile function and the ability to obtain and maintain one or several erections over the 36 hours following intake. 21, 25 Indeed, clinical trials conducted with orally administered, on-demand tadalafi l for patients with ED demonstrated real life improved sexual activity with prolonged windows of opportunity for sexual activity. Furthermore, the rate and extent of tadalafi l absorption are not affected by food. 24 To treat ED, tadalafi l should be taken no more than once daily (Cialis ® , summary of product characteristics). Steadystate plasma concentrations are reached after 5 days of once-daily intake and that regimen affords tadalafi l exposure 1.6 times greater than after a single oral dose. 26 A cumulative plasma exposure equivalent to on-demand doses of 16 mg and 8 mg could be obtained after 5 days of daily ingestion of 10 mg or 5 mg of tadalafi l. 9 Therefore, tadalafi l pharmacokinetic characteristics, particularly its long half-life (17.5 hours) and its sustained plasma concentrations after daily dosing, have made it one of the best candidates for once-daily dosing, which may be an attractive, alternative, oral treatment for patients with ED. Numerous clinical trials have shown the effi cacy, safety and tolerability of different tadalafi l doses taken once daily.
Two open-label studies compared the effi cacy and safety of once-daily versus on-demand tadalafi l. 27, 28 In the fi rst study, 112 men with moderate-to-severe ED previously unresponsive to on-demand tadalafi l were treated with 10 mg tadalafi l once daily. 27 The 10 mg daily dose resulted in mean improvement of IIEF scores of 12.8 and 8.2 compared to pretreatment and on-demand baseline values, respectively (p Ͻ 0.001), and 58% of intercourse attempts (as assessed with Sexual Encounter Profi le diary question 3 [SEP3]) were successfully completed (p Ͻ 0.001). More patients reported improved erections with once-daily compared to on-demand tadalafi l (69% versus 42%, respectively), demonstrating an effective salvage strategy for previous non-responders. The second study evaluated the effi cacy, safety and tolerability of on-demand 20 mg versus once-daily 10 mg tadalafi l in 145 men with mild to severe ED of various etiologies. 28 Once-daily tadalafi l was associated with a better effi cacy profi le compared with on-demand tadalafi l. All the patients experienced signifi cant improvement in the IIEF-erectile function (EF) domain, but with mean once-daily dose changes signifi cantly higher than for on-demand tadalafi l (p Ͻ 0.05). Moreover, patients taking once-daily tadalafi l successfully completed sexual intercourse significantly more frequently than the patients taking tadalafi l on-demand (p Ͻ 0.05). In that study, 72% of the patients expressed a preference for once-daily dosing. Based on the results of those two open-label studies, the authors concluded that the effi cacy of once-daily tadalafi l appeared to be better than that of on-demand use.
An initial 12-week, randomized, double-blind and parallel-group study was conducted on 268 men with ED. 9 The primary outcome end points were changes of IIEF-EF, Sexual Encounter Profi le (SEP) question 2 (SEP2; "Where you able to insert your penis into partner's vagina?") and SEP3 ("Did your erection last long enough for you to have successful intercourse?") questions. Treatment tolerability and safety were also assessed. For patients treated with placebo or once-daily 5 mg or 10 mg tadalafi l, respective score modifi cations from baseline to end point were: 0.9%, 9.7% and 9.4% for the IIEF-EF; 11.2%, 36.5% and 39.4% for SEP2; and of 13.2%, 45.5% and 50.1% for SEP3. At the end of the study and for the respective treatment groups, 28.3%, 84.5% and 84.6% of the patients reported improved erections, and 8.3%, 51.5% and 50.5% reported "no ED" (defi ned as IIEF [26] [27] [28] [29] [30] . All comparisons between tadalafi l (5 mg or 10 mg) and placebo were highly signifi cant (p Ͻ 0.001). The results also showed that once-daily 5-mg or 10-mg tadalafi l was well tolerated. Adverse events described by at least 5% of the patients were: dyspepsia, headaches, back pain, upper abdominal pain and myalgias. Only nine (3.4%) patients discontinued therapy because of adverse events.
More recently, the effi cacy and safety of lower tadalafi l doses taken once daily to treat ED was assessed in a randomized, double-blind, placebo-controlled, paralleldesign study in the US. 10 Responses to once-daily 2.5 mg or 5 mg tadalafi l were compared to placebo, for 24 weeks. The primary effi cacy endpoints were change from baseline to 24 weeks in mean IIEF-EF domain score, SEP2 and SEP3. Changes in the Psychological And Interpersonal Relationship Scales (PAIRS) were included in the secondary effi cacy endpoints. Effi cacy results indicated signifi cantly improved erectile function with tadalafi l versus placebo for all three primary study end points. At 24 weeks, more signifi cant mean changes from the baseline IIEF-EF scores were observed for the 2.5 mg (6.1) and 5 mg tadalafi l (7.0) groups compared to the placebo group (1.2) (p Ͻ 0.001); with respective baseline-to-end-point changes of 24.3%, 26.2% and 5.2% for SEP2; and 31.2%, 35.1% and 9.5% for SEP3 (p Ͻ 0.001). The effi cacy results were similar across the 24-week observation period, suggesting no treatment resistance. The effi cacy of the 5 mg tadalafi l dose was better than that of 2.5 mg tadalafi l. This apparent dose -response was observed for IIEF-EF domain scores and responses to SEP2 and SEP3 for patients with mild, moderate or severe ED. At 24 weeks, treatment with tadalafi l 2.5 and 5 mg improved PAIRS Sexual Self-confi dence Domain scores when compared with placebo (both p Ͻ 0.001), but with no signifi cant differences in the PAIRS Spontaneity Domain scores. Both once-daily tadalafi l doses were well tolerated, with low discontinuation rates because of adverse events and a low treatment emergent CVTEAE rate.
Based on the review and evaluation of data from these phase III, randomized, double-blind, placebo-controlled studies, the European Commission approved 2.5 mg and 5 mg tadalafi l for once-daily treatment of ED in June 2007. Seven months later, in January 2008, the US Food and Drug Administration approved them. Data from all the clinical trials confi rmed that men with ED taking 2.5 mg or 5 mg tadalafi l once daily experienced improved erectile function compared with those taking a placebo. When taken without restrictions on the timing of sexual activity, once-daily tadalafi l was able to improve erectile function over the course of therapy. Moreover, a recent publication reporting on two open-label extension studies showed that once-daily 5 mg tadalafi l for up to 2 years was effective, making it a valid alternative to on-demand tadalafi l for men with ED. 29 Therefore, when tadalafi l is taken daily, men can attempt sexual activity at any time. As part of a daily regimen, tadalafi l may be taken at 2.5 mg or increased to 5 mg, based on individual effi cacy and tolerability. This low-dose, oncedaily tadalafi l treatment option may be most appropriate for men with ED who anticipate more frequent sexual activity (eg, twice weekly). Furthermore, the couples who like to have choices or want to go back to a certain freedom in their sexual lives will appreciate the availability of a PDE5 inhibitor for once-daily use. For the other men and their partners, treatment with on-demand tadalafi l taken will remain an appropriate regimen.
Adverse events reported by the patients taking on-demand tadalafi l were mainly headaches, upset stomach, nasal congestion, backache, muscle aches, dizziness and fl ushing. In clinical trials of once-daily tadalafi l, the most commonly reported adverse events were headaches, indigestion, back pain, muscle aches, nasal congestion, fl ushing and limb pain. Most adverse events reported for on-demand or once-daily tadalafi l were transient and generally mild or moderate. 9, 10 Just as on-demand tadalafi l has been shown to be safe and well tolerated when taken for up to 2 years, 30 two dosing studies of long-term, open-label, once-daily tadafi l provided evidence that 5 mg tadalafi l was also well tolerated for up to 2 years in men with ED. 29 As for the other PDE5 inhibitors, tadalafi l is contraindicated for patients taking nitrates, those with cardiac disease for whom sexual activity is not recommended, and those with non-arteritic anterior ischemic optic neuropathy. Oncedaily tadalafi l assures continuous plasma levels, which should be considered when evaluating the potential for interactions with certain medications (eg, nitrates, alphablockers, anti-hypertensives and potent CYP3A4 inhibitors) and with substantial amounts of alcohol. PDE5 inhibitors were previously shown to cause no changes in seminal parameters. 31 A multicenter, randomized, double-blind, placebo-controlled study demonstrated that once-daily 20 mg tadalafi l for 9 months (approximately three human spermatogenesis cycles) had no major adverse effects on sperm production or reproductive hormones in healthy men (or those with mild ED) at least 45 years old. 32 More interestingly, PDE5-inhibitor use by men without ED may lead to a marked reduction of the post-ejaculatory refractory time, indicating that, in normal subjects, PDE5-inhibitor intake may have a positive infl uence on retumescence following ejaculation in the presence of a continuous erotic stimulation. 31, [33] [34] [35] Since once-daily tadalafi l (2.5, 5 or 10 mg) was proven effective and well tolerated in the general ED population, a recent study was undertaken to determine the effi cacy and tolerability of once-daily 2.5 mg or 5 mg tadalafi l by men with ED and diabetes. 32 This randomized, double-blind, placebo-controlled, multicenter, 12-week study enrolled 298 men with diabetes and ED. Patients who took either tadalafi l dose had clinically and signifi cantly improved IIEF-EF and mean success rates for vaginal penetration, completion of intercourse, and overall treatment satisfaction (p Յ 0.005 vs placebo). These results suggest that once-daily 2.5 mg or 5 mg tadalafi l may be a good alternative to on-demand therapy for some men with diabetes and ED, eliminating the need to plan sex within a limited time frame.
Conclusion
The primary purpose of this review was to summarize patient and partner viewpoints on ED management with PDE5 inhibitors, and help determine whether once-daily tadalafi l can improve some psychological aspects (such as sexual self-confi dence, spontaneity and time concerns) compared to on-demand tadalafi l or other PDE5 inhibitors in these patients.
When approved in 2003, on-demand 10 mg or 20 mg tadalafi l was the fi rst and only PDE5 inhibitor clinically proven to provide sustained effi cacy for up to 36 hours. It transformed the oral treatment of ED by giving men the ability to achieve an erection long after taking the drug. Once-daily 2.5 mg or 5 mg tadalafi l provides a new therapeutic alternative for men, who may be looking for a dosing option that avoids scheduling sexual activity, and for couples, who may prefer more convenience and spontaneity in their sexual lives. Taking once daily tadalafi l at a lower dose may be as effective as taking higher on-demand doses, and appears to be safe. In agreement with their physicians, patients now have the freedom to choose the dosing regimen most appropriate for them. Some may prefer the up to 36 hours of effi cacy provided by on-demand tadalafi l while others may want the unique benefi t provided by the new once-daily dosing option.
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